MACROGENICS, INC. Operating Lease Cost
MACROGENICS, INC. (MGNX) reported Operating Lease Cost of $6.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-09
- MACROGENICS, INC. operating lease, cost for the quarter ending 2019-12-31 was $1.38M.
- MACROGENICS, INC. operating lease, cost for the quarter ending 2019-09-30 was $1.38M.
- MACROGENICS, INC. operating lease, cost for the quarter ending 2019-06-30 was $1.36M.
- MACROGENICS, INC. operating lease, cost for the quarter ending 2019-03-31 was $1.34M.
- MACROGENICS, INC. operating lease, cost for fiscal 2025 was $6.10M, a 7.73% decline from fiscal 2024.
- MACROGENICS, INC. operating lease, cost for fiscal 2024 was $6.61M, a 11.38% decline from fiscal 2023.
- MACROGENICS, INC. operating lease, cost for fiscal 2023 was $7.46M, a 33.27% increase from fiscal 2022.
- MACROGENICS, INC. operating lease, cost for fiscal 2022 was $5.60M, a 0.29% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.10M 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $6.61M 10-K · filed 2026-03-09 | |||
| 2023-12-31 | $7.46M 10-K · filed 2025-03-20 | |||
| 2022-12-31 | $5.60M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $5.61M 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $5.41M 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.76M derived: sum of 2 quarters · filed 2021-02-25 | $4.12M derived: sum of 3 quarters · filed 2021-02-25 | $5.46M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $2.74M derived: sum of 2 quarters · filed 2019-11-06 | $4.08M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $2.70M 10-Q · filed 2019-07-31 | ||
| 2019-03-31 | $1.34M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |